CALC

SEC source: 0001415889-24-001830 · form4-01252024_080106.xml · derivative · entry 20

Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner

Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner

Sanderling Ventures Management VI · CIK 0001429588 · 10% owner

Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner

Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner

Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner

Sanderling Ventures Management VII · CIK 0001993457 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Sanderling Ventures Management VII

Disclosed balance after: 14,372

Underlying: Common Stock · 14,372 shares

Expires 2024-12-31

F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.

F2 · derivative.exercise_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter.

F2 · derivative.expiration_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter.

SEC source: 0001415889-24-001830 · form4-01252024_080106.xml · derivative · entry 19

Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner

Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner

Sanderling Ventures Management VI · CIK 0001429588 · 10% owner

Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner

Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner

Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner

Sanderling Ventures Management VII · CIK 0001993457 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Sanderling Ventures Management VI

Disclosed balance after: 1,960

Underlying: Common Stock · 1,960 shares

Expires 2026-12-31

F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.

F3 · derivative.exercise_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter.

F3 · derivative.expiration_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter.

SEC source: 0001415889-24-001830 · form4-01252024_080106.xml · derivative · entry 18

Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner

Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner

Sanderling Ventures Management VI · CIK 0001429588 · 10% owner

Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner

Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner

Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner

Sanderling Ventures Management VII · CIK 0001993457 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Sanderling Ventures Management VI

Disclosed balance after: 1,960

Underlying: Common Stock · 1,960 shares

Expires 2024-12-31

F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.

F2 · derivative.exercise_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter.

F2 · derivative.expiration_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter.

SEC source: 0001415889-24-001830 · form4-01252024_080106.xml · derivative · entry 17

Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner

Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner

Sanderling Ventures Management VI · CIK 0001429588 · 10% owner

Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner

Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner

Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner

Sanderling Ventures Management VII · CIK 0001993457 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Sanderling Ventures VII Annex Fund, L.P.

Disclosed balance after: 6,592

Underlying: Common Stock · 6,592 shares

Expires 2026-12-31

F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.

F3 · derivative.exercise_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter.

F3 · derivative.expiration_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter.

SEC source: 0001415889-24-001830 · form4-01252024_080106.xml · derivative · entry 16

Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner

Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner

Sanderling Ventures Management VI · CIK 0001429588 · 10% owner

Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner

Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner

Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner

Sanderling Ventures Management VII · CIK 0001993457 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Sanderling Ventures VII Annex Fund, L.P.

Disclosed balance after: 6,592

Underlying: Common Stock · 6,592 shares

Expires 2024-12-31

F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.

F2 · derivative.exercise_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter.

F2 · derivative.expiration_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter.

SEC source: 0001415889-24-001830 · form4-01252024_080106.xml · derivative · entry 15

Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner

Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner

Sanderling Ventures Management VI · CIK 0001429588 · 10% owner

Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner

Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner

Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner

Sanderling Ventures Management VII · CIK 0001993457 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Sanderling Ventures VII (Canada), L.P.

Disclosed balance after: 25,516

Underlying: Common Stock · 25,516 shares

Expires 2026-12-31

F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.

F3 · derivative.exercise_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter.

F3 · derivative.expiration_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter.

SEC source: 0001415889-24-001830 · form4-01252024_080106.xml · derivative · entry 14

Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner

Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner

Sanderling Ventures Management VI · CIK 0001429588 · 10% owner

Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner

Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner

Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner

Sanderling Ventures Management VII · CIK 0001993457 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Sanderling Ventures VII (Canada), L.P.

Disclosed balance after: 25,516

Underlying: Common Stock · 25,516 shares

Expires 2024-12-31

F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.

F2 · derivative.exercise_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter.

F2 · derivative.expiration_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter.

SEC source: 0001415889-24-001830 · form4-01252024_080106.xml · derivative · entry 13

Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner

Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner

Sanderling Ventures Management VI · CIK 0001429588 · 10% owner

Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner

Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner

Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner

Sanderling Ventures Management VII · CIK 0001993457 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Sanderling Ventures VII, L.P.

Disclosed balance after: 97,236

Underlying: Common Stock · 97,236 shares

Expires 2026-12-31

F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.

F3 · derivative.exercise_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter.

F3 · derivative.expiration_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter.

SEC source: 0001415889-24-001830 · form4-01252024_080106.xml · derivative · entry 12

Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner

Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner

Sanderling Ventures Management VI · CIK 0001429588 · 10% owner

Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner

Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner

Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner

Sanderling Ventures Management VII · CIK 0001993457 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Sanderling Ventures VII, L.P.

Disclosed balance after: 97,236

Underlying: Common Stock · 97,236 shares

Expires 2024-12-31

F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.

F2 · derivative.exercise_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter.

F2 · derivative.expiration_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter.

SEC source: 0001415889-24-001830 · form4-01252024_080106.xml · derivative · entry 11

Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner

Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner

Sanderling Ventures Management VI · CIK 0001429588 · 10% owner

Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner

Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner

Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner

Sanderling Ventures Management VII · CIK 0001993457 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Sanderling Venture Partners VI Co-Investment Fund, L.P.

Disclosed balance after: 72,338

Underlying: Common Stock · 72,338 shares

Expires 2026-12-31

F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.

F3 · derivative.exercise_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter.

F3 · derivative.expiration_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter.

SEC source: 0001415889-24-001830 · form4-01252024_080106.xml · derivative · entry 10

Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner

Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner

Sanderling Ventures Management VI · CIK 0001429588 · 10% owner

Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner

Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner

Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner

Sanderling Ventures Management VII · CIK 0001993457 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Sanderling Venture Partners VI Co-Investment Fund, L.P.

Disclosed balance after: 72,338

Underlying: Common Stock · 72,338 shares

Expires 2024-12-31

F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.

F2 · derivative.exercise_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter.

F2 · derivative.expiration_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter.

SEC source: 0001415889-24-001830 · form4-01252024_080106.xml · derivative · entry 9

Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner

Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner

Sanderling Ventures Management VI · CIK 0001429588 · 10% owner

Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner

Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner

Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner

Sanderling Ventures Management VII · CIK 0001993457 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 121,678

Underlying: Common Stock · 121,678 shares

Expires 2026-12-31

F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.

F3 · derivative.exercise_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter.

F3 · derivative.expiration_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter.

SEC source: 0001415889-24-001830 · form4-01252024_080106.xml · derivative · entry 8

Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner

Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner

Sanderling Ventures Management VI · CIK 0001429588 · 10% owner

Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner

Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner

Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner

Sanderling Ventures Management VII · CIK 0001993457 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 121,678

Underlying: Common Stock · 121,678 shares

Expires 2024-12-31

F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.

F2 · derivative.exercise_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter.

F2 · derivative.expiration_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter.

SEC source: 0001415889-24-001830 · form4-01252024_080106.xml · nonDerivative · entry 7

Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner

Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner

Sanderling Ventures Management VI · CIK 0001429588 · 10% owner

Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner

Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner

Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner

Sanderling Ventures Management VII · CIK 0001993457 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Sanderling Ventures Management VII

Disclosed balance after: 30,292

F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.

SEC source: 0001415889-24-001830 · form4-01252024_080106.xml · nonDerivative · entry 6

Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner

Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner

Sanderling Ventures Management VI · CIK 0001429588 · 10% owner

Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner

Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner

Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner

Sanderling Ventures Management VII · CIK 0001993457 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Sanderling Ventures Management VI

Disclosed balance after: 21,602

F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.

SEC source: 0001415889-24-001830 · form4-01252024_080106.xml · nonDerivative · entry 5

Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner

Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner

Sanderling Ventures Management VI · CIK 0001429588 · 10% owner

Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner

Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner

Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner

Sanderling Ventures Management VII · CIK 0001993457 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Sanderling Ventures VII Annex Fund, L.P.

Disclosed balance after: 27,609

F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.

SEC source: 0001415889-24-001830 · form4-01252024_080106.xml · nonDerivative · entry 4

Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner

Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner

Sanderling Ventures Management VI · CIK 0001429588 · 10% owner

Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner

Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner

Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner

Sanderling Ventures Management VII · CIK 0001993457 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Sanderling Ventures VII (Canada), L.P.

Disclosed balance after: 114,260

F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.

SEC source: 0001415889-24-001830 · form4-01252024_080106.xml · nonDerivative · entry 3

Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner

Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner

Sanderling Ventures Management VI · CIK 0001429588 · 10% owner

Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner

Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner

Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner

Sanderling Ventures Management VII · CIK 0001993457 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Sanderling Ventures VII, L.P.

Disclosed balance after: 435,148

F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.

SEC source: 0001415889-24-001830 · form4-01252024_080106.xml · nonDerivative · entry 2

Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner

Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner

Sanderling Ventures Management VI · CIK 0001429588 · 10% owner

Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner

Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner

Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner

Sanderling Ventures Management VII · CIK 0001993457 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Sanderling Venture Partners VI Co-Investment Fund, L.P.

Disclosed balance after: 727,433

F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.

SEC source: 0001415889-24-001830 · form4-01252024_080106.xml · nonDerivative · entry 1

Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner

Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner

Sanderling Ventures Management VI · CIK 0001429588 · 10% owner

Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner

Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner

Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner

Sanderling Ventures Management VII · CIK 0001993457 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 946,744

F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.

SEC source: 0001415889-24-001828 · form4-01252024_080101.xml · derivative · entry 7

Leheny A. Rachel · CIK 0001484729 · Director · CHIEF EXECUTIVE OFFICER · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,543

Underlying: Common Stock · 45,543 shares

Expires 2026-12-31

F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.

F4 · derivative.exercise_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter.

F4 · derivative.expiration_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter.

SEC source: 0001415889-24-001828 · form4-01252024_080101.xml · derivative · entry 6

Leheny A. Rachel · CIK 0001484729 · Director · CHIEF EXECUTIVE OFFICER · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,543

Underlying: Common Stock · 45,543 shares

Expires 2024-12-31

F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.

F3 · derivative.exercise_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter.

F3 · derivative.expiration_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter.

SEC source: 0001415889-24-001828 · form4-01252024_080101.xml · nonDerivative · entry 1

Leheny A. Rachel · CIK 0001484729 · Director · CHIEF EXECUTIVE OFFICER · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 109,926

F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.

SEC source: 0001415889-24-001831 · form4-01252024_080106.xml · derivative · entry 23

MIDDLETON FRED A · CIK 0001267959 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Sanderling Ventures Management VII

Disclosed balance after: 14,372

Underlying: Common Stock · 14,372 shares

Expires 2026-12-31

F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.

F8 · derivative.exercise_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter.

F8 · derivative.expiration_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter.

F5 · ownership.nature: The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VII Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001415889-24-001831 · form4-01252024_080106.xml · derivative · entry 22

MIDDLETON FRED A · CIK 0001267959 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Sanderling Ventures Management VII

Disclosed balance after: 14,372

Underlying: Common Stock · 14,372 shares

Expires 2024-12-31

F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.

F7 · derivative.exercise_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter.

F7 · derivative.expiration_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter.

F5 · ownership.nature: The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VII Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001415889-24-001831 · form4-01252024_080106.xml · derivative · entry 21

MIDDLETON FRED A · CIK 0001267959 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Sanderling Ventures Management VI

Disclosed balance after: 1,960

Underlying: Common Stock · 1,960 shares

Expires 2026-12-31

F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.

F8 · derivative.exercise_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter.

F8 · derivative.expiration_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter.

F3 · ownership.nature: The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VI Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001415889-24-001831 · form4-01252024_080106.xml · derivative · entry 20

MIDDLETON FRED A · CIK 0001267959 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Sanderling Ventures Management VI

Disclosed balance after: 1,960

Underlying: Common Stock · 1,960 shares

Expires 2024-12-31

F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.

F7 · derivative.exercise_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter.

F7 · derivative.expiration_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter.

F3 · ownership.nature: The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VI Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001415889-24-001831 · form4-01252024_080106.xml · derivative · entry 19

MIDDLETON FRED A · CIK 0001267959 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Sanderling Ventures VII Annex Fund, L.P.

Disclosed balance after: 6,592

Underlying: Common Stock · 6,592 shares

Expires 2026-12-31

F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.

F8 · derivative.exercise_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter.

F8 · derivative.expiration_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter.

F5 · ownership.nature: The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VII Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001415889-24-001831 · form4-01252024_080106.xml · derivative · entry 18

MIDDLETON FRED A · CIK 0001267959 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Sanderling Ventures VII Annex Fund, L.P.

Disclosed balance after: 6,592

Underlying: Common Stock · 6,592 shares

Expires 2024-12-31

F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.

F7 · derivative.exercise_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter.

F7 · derivative.expiration_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter.

F5 · ownership.nature: The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VII Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001415889-24-001831 · form4-01252024_080106.xml · derivative · entry 17

MIDDLETON FRED A · CIK 0001267959 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Sanderling Ventures VII (Canada), L.P.

Disclosed balance after: 25,516

Underlying: Common Stock · 25,516 shares

Expires 2026-12-31

F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.

F8 · derivative.exercise_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter.

F8 · derivative.expiration_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter.

F5 · ownership.nature: The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VII Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001415889-24-001831 · form4-01252024_080106.xml · derivative · entry 16

MIDDLETON FRED A · CIK 0001267959 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Sanderling Ventures VII (Canada), L.P.

Disclosed balance after: 25,516

Underlying: Common Stock · 25,516 shares

Expires 2024-12-31

F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.

F7 · derivative.exercise_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter.

F7 · derivative.expiration_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter.

F5 · ownership.nature: The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VII Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001415889-24-001831 · form4-01252024_080106.xml · derivative · entry 15

MIDDLETON FRED A · CIK 0001267959 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Sanderling Ventures VII, L.P.

Disclosed balance after: 97,236

Underlying: Common Stock · 97,236 shares

Expires 2026-12-31

F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.

F8 · derivative.exercise_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter.

F8 · derivative.expiration_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter.

F5 · ownership.nature: The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VII Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001415889-24-001831 · form4-01252024_080106.xml · derivative · entry 14

MIDDLETON FRED A · CIK 0001267959 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Sanderling Ventures VII, L.P.

Disclosed balance after: 97,236

Underlying: Common Stock · 97,236 shares

Expires 2024-12-31

F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.

F7 · derivative.exercise_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter.

F7 · derivative.expiration_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter.

F5 · ownership.nature: The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VII Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001415889-24-001831 · form4-01252024_080106.xml · derivative · entry 13

MIDDLETON FRED A · CIK 0001267959 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Sanderling Venture Partners VI Co-Investment Fund, L.P.

Disclosed balance after: 72,338

Underlying: Common Stock · 72,338 shares

Expires 2026-12-31

F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.

F8 · derivative.exercise_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter.

F8 · derivative.expiration_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter.

F3 · ownership.nature: The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VI Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001415889-24-001831 · form4-01252024_080106.xml · derivative · entry 12

MIDDLETON FRED A · CIK 0001267959 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Sanderling Venture Partners VI Co-Investment Fund, L.P.

Disclosed balance after: 72,338

Underlying: Common Stock · 72,338 shares

Expires 2024-12-31

F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.

F7 · derivative.exercise_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter.

F7 · derivative.expiration_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter.

F3 · ownership.nature: The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VI Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001415889-24-001831 · form4-01252024_080106.xml · derivative · entry 11

MIDDLETON FRED A · CIK 0001267959 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Sanderling Venture Partners VI, LP

Disclosed balance after: 121,678

Underlying: Common Stock · 121,678 shares

Expires 2026-12-31

F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.

F8 · derivative.exercise_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter.

F8 · derivative.expiration_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter.

F3 · ownership.nature: The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VI Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001415889-24-001831 · form4-01252024_080106.xml · derivative · entry 10

MIDDLETON FRED A · CIK 0001267959 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Sanderling Venture Partners VI, LP

Disclosed balance after: 121,678

Underlying: Common Stock · 121,678 shares

Expires 2024-12-31

F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.

F7 · derivative.exercise_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter.

F7 · derivative.expiration_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter.

F3 · ownership.nature: The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VI Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001415889-24-001831 · form4-01252024_080106.xml · nonDerivative · entry 7

MIDDLETON FRED A · CIK 0001267959 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Sanderling Ventures Management VII

Disclosed balance after: 30,292

F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.

F5 · ownership.nature: The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VII Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001415889-24-001831 · form4-01252024_080106.xml · nonDerivative · entry 6

MIDDLETON FRED A · CIK 0001267959 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Sanderling Ventures Management VI

Disclosed balance after: 21,602

F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.

F3 · ownership.nature: The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VI Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001415889-24-001831 · form4-01252024_080106.xml · nonDerivative · entry 5

MIDDLETON FRED A · CIK 0001267959 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Sanderling Ventures VII Annex Fund, L.P.

Disclosed balance after: 27,609

F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.

F4 · ownership.nature: The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the securities of the Issuer held by Sanderling Ventures VII, LP ("SVP VII, LP", together with Sanderling Ventures Management VII, Sanderling Ventures VII (Canada), L.P. and Sanderling Ventures VII Annex Fund, L.P., the "Sanderling VII Shares"). The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001415889-24-001831 · form4-01252024_080106.xml · nonDerivative · entry 4

MIDDLETON FRED A · CIK 0001267959 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Sanderling Ventures VII (Canada), L.P.

Disclosed balance after: 114,260

F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.

F5 · ownership.nature: The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VII Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001415889-24-001831 · form4-01252024_080106.xml · nonDerivative · entry 3

MIDDLETON FRED A · CIK 0001267959 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Sanderling Ventures VII, L.P.

Disclosed balance after: 435,148

F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.

F4 · ownership.nature: The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the securities of the Issuer held by Sanderling Ventures VII, LP ("SVP VII, LP", together with Sanderling Ventures Management VII, Sanderling Ventures VII (Canada), L.P. and Sanderling Ventures VII Annex Fund, L.P., the "Sanderling VII Shares"). The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001415889-24-001831 · form4-01252024_080106.xml · nonDerivative · entry 2

MIDDLETON FRED A · CIK 0001267959 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Sanderling Venture Partners VI Co-Investment Fund, L.P.

Disclosed balance after: 727,433

F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.

F3 · ownership.nature: The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VI Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001415889-24-001831 · form4-01252024_080106.xml · nonDerivative · entry 1

MIDDLETON FRED A · CIK 0001267959 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Sanderling Venture Partners VI, LP

Disclosed balance after: 946,744

F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.

F2 · ownership.nature: The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the securities of the Issuer held by Sanderling Venture Partners VI, LP ("SVP VI, LP", together with Sanderling Venture Partners VI Co-Investment Fund, L.P., Sanderling VI Beteiligungs GmbH & Co. KG, Sanderling Ventures Management VI and Sanderling VI Limited Partnership (the "Sanderling VI Shares"). The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001415889-24-001829 · form4-01252024_080102.xml · derivative · entry 3

WILSON ROBERT N · CIK 0001189022 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,157

Underlying: Common Stock · 34,157 shares

Expires 2026-12-31

F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.

F3 · derivative.exercise_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter.

F3 · derivative.expiration_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter.

SEC source: 0001415889-24-001829 · form4-01252024_080102.xml · derivative · entry 2

WILSON ROBERT N · CIK 0001189022 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,157

Underlying: Common Stock · 34,157 shares

Expires 2024-12-31

F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.

F2 · derivative.exercise_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter.

F2 · derivative.expiration_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter.

SEC source: 0001415889-24-001829 · form4-01252024_080102.xml · nonDerivative · entry 1

WILSON ROBERT N · CIK 0001189022 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 250,475

F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.

SEC source: 0001209191-23-058568 · doc4.xml · nonDerivative · entry 1

WILSON ROBERT N · CIK 0001189022 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 182,161

SEC source: 0001209191-23-054770 · doc4.xml · nonDerivative · entry 1

Leheny A. Rachel · CIK 0001484729 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,840

F1 · price: The weighted average purchase price for the transaction reported was $3.34, and the range of prices were between $3.30 and $3.38. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.

SEC source: 0001209191-23-054633 · doc4.xml · nonDerivative · entry 1

Leheny A. Rachel · CIK 0001484729 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,840

F1 · price: The weighted average purchase price for the transaction reported was $3.1208, and the range of prices were between $3.11 and $3.17. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.